Nanobiotix S.A.
NBTX
$28.23
-$2.08-6.86%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 326.50% | 292.10% | -158.54% | -159.72% | -- |
| Total Other Revenue | -42.32% | -46.97% | -55.19% | -54.29% | -6.13% |
| Total Revenue | 202.38% | 177.99% | -149.57% | -150.57% | 178.93% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 202.38% | 177.99% | -149.57% | -150.57% | 178.93% |
| SG&A Expenses | 10.07% | 1.19% | -14.19% | -12.46% | -1.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.00% | -23.70% | -11.98% | -10.21% | 13.15% |
| Operating Income | 103.65% | 103.36% | -3,988.24% | -4,066.11% | 8.36% |
| Income Before Tax | 73.91% | 76.01% | -299.22% | -307.25% | 23.53% |
| Income Tax Expenses | -95.61% | -95.91% | -136.35% | -137.05% | 4,743.75% |
| Earnings from Continuing Operations | 74.05% | 76.14% | -294.83% | -302.77% | 23.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.05% | 76.14% | -294.83% | -302.77% | 23.03% |
| EBIT | 103.65% | 103.36% | -3,988.24% | -4,066.11% | 8.36% |
| EBITDA | 105.06% | 104.65% | -3,212.83% | -3,275.32% | 8.76% |
| EPS Basic | 74.22% | 76.30% | -223.24% | -229.89% | 42.77% |
| Normalized Basic EPS | 72.41% | 74.63% | -853.59% | -872.68% | 38.15% |
| EPS Diluted | 74.22% | 76.30% | -217.21% | -223.59% | 42.77% |
| Normalized Diluted EPS | 72.41% | 74.63% | -853.59% | -872.68% | 38.15% |
| Average Basic Shares Outstanding | 0.62% | 0.62% | 22.12% | 22.12% | 34.50% |
| Average Diluted Shares Outstanding | 0.62% | 0.62% | 22.12% | 22.12% | 34.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |